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Health & Services
Evaluation of Guideline-Directed Medication Therapy for Heart Failure with 
Reduced Ejection Fraction Patients at Discharge on 30-Day Readmission Rates at 
Two Tertiary Healthcare Centers 
Jacqueline Hesse, Pharm.D.; Yan Xu, Pharm.D., BCPS, BCCP; Meri Slavica, RPh., Ph.D., BCPS; James Watkins, 2020 Pharm.D. 
Candidate; Alan Rankin, MD; Joshua Remick, MD  
Background Discussion
• Heart failure with reduced ejection fraction (HFrEF) is a 
chronic, progressive disease leading to symptoms such 
as dyspnea, cough, edema, and exercise intolerance.1
• The use of an angiotensin converting enzyme inhibitor 
(ACEi), angiotensin II receptor blocker (ARB), or 
angiotensin receptor-neprilysin inhibitor (ARNI) in 
combination with an evidence-based beta blocker (BB) is 
guideline-supported Class I recommended therapy for 
HFrEF with an LVEF <40%.1
• Multiple studies of these medication classes have shown 
improvement in HFrEF patient morbidity, as well as 
decrease in hospital readmission rates.1,3
• The MERIT-HF and COPERNICUS trials 
validated the benefit of BB use in HFrEF.4,5
• PARADIGM-HF led to the approval of 
Sacubitril/Valsartan (Entresto®) and was 
stopped prematurely due to the reduction 
in hospitalizations in the treatment group.3
• Although many pharmacologic treatments are available 
for this population, patients are often readmitted soon 
after discharge.
o Every year In the United States there are 
over 1 million hospitalizations for heart 
failure, and 25% of these patients are 
readmitted.
o Between 2018 and 2019, the readmission 
rate for all CHF within 30 days at our two 
medical centers was 13.6%-15.07%. 
Approximately 50% of these are estimated 
to be due to HFrEF, which is what this 
research will be evaluating.
o While prior literature supports the clinical benefits of 
guideline-directed medication therapy (GDMT) in HFrEF-
related readmissions, these potential benefits had not 
previously been evaluated at our two tertiary medical 
centers.
Objectives
Primary Objective
Assess the impact of discharging patients on GDMT in the 
HFrEF population on 30-day readmission rates at two 
tertiary medical centers
Secondary Objectives
• Identify relationships between serum creatinine (SCr), 
potassium (K), and systolic blood pressure (SBP) and 
GDTM on which patients were discharged
• Determine if a correlation exists between cause of HFrEF 
and readmission rates
Methodology
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Study Design
Retrospective chart review of patients admitted to either one 
of our two tertiary medical centers from January 1, 2018 to 
December 31, 2019 with a primary diagnosis of HFrEF
Inclusion Criteria
Patients must be > 18 years of age and have an LVEF <40%
Exclusion Criteria
Patients who had a history of angioedema as a result of ACE, 
ARB, or ARNI use, or any hypersensitivity or unacceptable 
side effects to an ACEi, ARB, ARNI, or BB
Data Collection
• Readmission to either of our tertiary medical centers within 
30 days of discharge, or no readmission
• GDMT prescribed on discharge
• Highest SCr on readmission (if applicable)
• Highest K on readmission (if applicable)
• Lowest SBP on readmission (if applicable)
• Cause of HFrEF
• Incidence of angioedema 
Conclusion
Patient Baseline Characteristics
Primary Outcome
Table 1. Baseline characteristics Table 2. Combined thirty-day readmission rates by GDMT
Therapy at 
Discharge
Readmission 
with the 
Therapy
Readmission 
without the 
Therapy
Association Tests
N =  360 N = 650 p-value OR (95% CI)
Any ACEi or 
ARB 
93 109 0.0283 1.4 (1.0,1.9)
Any ARNI 18 184 0.2171 0.7 (0.4,1.2)
Any BB 158 44 0.1234 0.8 (0.5,1.1)
ACEi or ARB 
and BB
82 120 0.0858 1.3 (1.0,1.8)
ARNI and BB 9 193 0.8853 1.1 (0.5,2.2)
Any GDMT 178 24 0.0369 0.6 (0.4,1.0)
*Association tests performed with Chi-square or Fisher tests
Characteristic Study Population (N = 1,247)
Age – Years (Mean) 68 (range 20-98)
Cause of HF
Ischemic cardiomyopathy 244 (20%)
Non-ischemic cardiomyopathy 394 (32%)
Idiopathic cause 609 (49%)
Discharged on GDMT
ACEi or ARB only 87 (7%)
Entresto (ARNI) only 28 (2%)
Beta blocker (BB) only 288 (23%)
ACEi or ARB and BB 575 (46%)
ARNI and BB 58 (5%)
No GDMT 211 (17%)
Readmitted within 30 days 202 (16%)
Primary Outcome
Secondary Outcomes
Figure 1. Thirty-day readmission rates by guideline-directed medication therapy (GDMT)
Figure 2. Thirty-day readmission rates by cause of HFrEF
Figure 4. Mean highest SCr on readmission
Figure 3. Mean highest K on readmission
Figure 5. Mean lowest SBP on readmission
All statistical analysis was performed by Providence biostatistician Shih-Ting Chiu
*16 (8%) of SBP readings were not available
ACEi/ARB ACEi/ARB and BB ARNI and BB
With 
GDMT
No GDMT With 
GDMT
No GDMT With 
GDMT
No GDMT
Mean 1.6 2.6 1.7 2.4 1.7 2.2
SD 1.0 1.7 1.0 1.7 0.6 1.5
P-value <0.0001 0.0002 0.0443
Table 3. Mean highest SCr on readmission
ACE/ARB ARNI BB ACE/ARB 
and BB
ARNI and 
BB
Any 
GDMT
Mean 87.9 83.2 89.6 88.3 80.0 89.1
SD 16.3 12.3 15.9 16.8 11.8 15.6
P-value 0.7923 0.1918 0.0135 0.9179 0.1157 0.0081
Table 4. Mean lowest SBP on readmission
Patients admitted between January 1, 2018 and December 
31, 2019 with a primary diagnosis of HFrEF and an LVEF 
<40% that are discharged on any GDMT were found to have 
less readmissions for any reason within 30 days compared 
to those discharged without any GDMT. However, 
subgroups of individual GDMT may not have a lower rate of 
readmission. SCr and SBP may be impacted by type of 
GDMT on which patients were discharged, but no 
differences were found in potassium levels for any GDMT 
compared to patients discharged on no GDMT. No 
significant difference was detected in readmission rates 
based on the cause of heart failure. Further research with 
prospective randomized controlled trials is needed to 
determine statistical significance of subgroups of GDMT on 
the rate of readmission within 30 days.  
A total of 1,999 patient admissions underwent chart review  
with 752 not meeting inclusion criteria and 1,247 included in 
the final analysis.
Primary Outcome
• Patients discharged on any GDMT had significantly less 
readmission rates within 30 days than those discharged 
without any GDMT (p = 0.0369)
• Patients discharged on an ACEi or ARB alone had 
significantly more readmissions within 30 days than 
patients discharged on no GDMT (p = 0.0283)
• No other subgroups of GDMT showed statistically 
significant results for readmission rate
Cause of HFrEF
• No significant differences were found between 30-day 
readmission rate and cause of heart failure (p = 0.3769)
Incidence of Angioedema
• 1 patient discharged on an ARNI and BB, and 3 patients 
discharged on an ACE or ARB in combination with a BB 
had angioedema. All were nonsignificant
Highest SCr on Readmission
• Patients discharged on an ACEi or ARB or on an ACEi or 
ARB in combination with a BB yielded a significantly 
lower SCr on readmission compared to no GDMT (p = 
<0.0001 and p = 0.0002, respectively)
• Discharging on an ARNI and BB compared to not 
discharging on an ARNI and BB was also statistically 
significant for lower SCr (p = 0.0443)
Highest K on Readmission
• No significant differences were found between groups
Lowest SBP on Readmission
• Patients discharged on a BB or on any GDMT had a 
significantly higher SBP on readmission compared to no 
GDMT (p = 0.0135 and p = 0.0081, respectively)
Limitations
• Retrospective chart review
• Overlapping GDMT variables
• Only 30-day readmissions reported, did not follow 
readmissions at a later point in time
• Some patients discharged on no GDMT had died during 
their admission
